Erschienen in:
21.04.2023 | Acute Pain Medicine (R Urman, Section Editor)
Low-Dose Initiation of Buprenorphine: A Narrative Review
verfasst von:
Amber N. Edinoff, MD, Omar H. Fahmy, MD, Noah J. Spillers, BS, Alexa R. Zaheri, BS, Eric D. Jackson, BS, Audrey J. De Witt, BS, Danielle M. Wenger, BS, Elyse M. Cornett, Ph.D, Kimberly L. Skidmore, MD, Adam M. Kaye, PharmD, Alan D. Kaye, MD, Ph.D
Erschienen in:
Current Pain and Headache Reports
|
Ausgabe 7/2023
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
Opioid use disorder (OUD) is a chronic disorder in which a person loses control over the use of opioids, develops a compulsive behavior, and defends the use despite knowing the negative consequences. There are numerous treatments for OUD, including buprenorphine. Since it is displacing a full agonist opioid, precipitated withdrawal can occur with standard inductions involving buprenorphine.
Recent Findings
Case reports have noted success with a low-dose initiation of buprenorphine, which is different from typical protocols, relatively limited by adverse effects when patients were recently administered full agonists. A cohort investigation studied the use of a transdermal patch as part of the protocol, which was fairly well tolerated.
Summary
While ongoing research is being conducted on this topic, recent case studies and smaller cohort studies have demonstrated the feasibility of a trial to treat OUD with low-dose initiation of buprenorphine.